Although pre-clinical data suggest that the T-DM1’s anti-tumor mechanism involves immune system activation, the clinical utility of peripheral blood immune cell subsets as prognostic markers in HER2-positive mBC patients receiving T-DM1 therapy remains to be elucidated. The gene discussed is ERBB2; the disease is neoplasm.